Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Net Income towards Common Stockholders (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Net Income towards Common Stockholders for 16 consecutive years, with -$8.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 184.45% to -$8.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$11.0 million, a 217.18% decrease, with the full-year FY2025 number at $23.4 million, up 235.53% from a year prior.
  • Net Income towards Common Stockholders was -$8.4 million for Q4 2025 at PharmaCyte Biotech, down from -$8.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $20.6 million in Q3 2024 to a low of -$8.4 million in Q4 2025.
  • A 5-year average of -$1.1 million and a median of -$1.5 million in 2022 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: plummeted 1945.33% in 2024, then soared 439.73% in 2025.
  • PharmaCyte Biotech's Net Income towards Common Stockholders stood at -$980837.0 in 2021, then tumbled by 91.72% to -$1.9 million in 2022, then dropped by 20.08% to -$2.3 million in 2023, then tumbled by 31.03% to -$3.0 million in 2024, then plummeted by 184.45% to -$8.4 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Net Income towards Common Stockholders are -$8.4 million (Q4 2025), -$8.4 million (Q3 2025), and $8.8 million (Q2 2025).